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Abstract
Introduction—Patients may receive cancer care from multiple institutions. However, at the 
population level, such patterns of cancer care are poorly described, complicating clinical research. 
To determine the population-based prevalence and characteristics of patients seen by multiple 
institutions, we used operations data from a state-mandated cancer registry.
Methods and materials—59,672 invasive cancers diagnosed in 1/1/2010-12/31/2011 in the 
Greater Bay Area of northern California were categorized as having been reported to the cancer 
registry within 365 days of diagnosis by: 1) ≥1 institution within an integrated health system 
(IHS); 2) IHS institution(s) and ≥1 non-IHS institution (e.g., private hospital); 3) 1 non-IHS 
institution; or 4) ≥2 non-IHS institutions. Multivariable logistic regression was used to 
characterize patients reported by multiple vs. single institutions.
Results—Overall in this region, 17% of cancers were reported by multiple institutions. Of the 
33% reported by an IHS, 8% were also reported by a non-IHS. Of non-IHS patients, 21% were 
reported by multiple institutions, with 28% for breast and 27% for pancreatic cancer, but 19%% 
for lung and 18% for prostate cancer. Generally, patients more likely to be seen by multiple 
institutions were younger or had more severe disease at diagnosis.
Conclusions—Population-based data show that one in six newly diagnosed cancer patients 
received care from multiple institutions, and differed from patients seen only at a single institution. 
Cancer care data from single institutions may be incomplete and possibly biased.
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1. Background
In the United States, patients may receive care for a given cancer from multiple institutions. 
When care is provided across multiple, non-integrated institutions, single institution medical 
record- based research, quality monitoring, or clinical learning systems [1–4] could be 
missing relevant tests, procedures or treatments [5]. Such research could thus be biased if it 
includes care only from a single institution [6]. Relatedly, research databases that aggregate 
de-identified records across institutions may double count the same patient seen at two 
institutions. Despite the importance of multi-institutional cancer care to clinical and health 
services research, little has been published describing the patterns of cancer care received 
across multiple institutions.
Cancer is unique among chronic diseases in the United States because all 50 states mandate 
that hospitals and private physicians report information to a central cancer registry about 
every patient newly diagnosed or seen for cancer [7]. Central cancer registries consolidate 
this information (abstracted per international standards) from all clinical reports in the 
population, including those from different institutions, into a single record for that cancer. 
However, the resulting research databases generally do not include details about the number 
and types of reporting institutions for each tumor. Thus, central cancer registry operations 
data, containing the unconsolidated records, provide a unique and underutilized opportunity 
to characterize cancer patients at the population-level according to the number of institutions 
at which they received care for a given cancer. Using such data from California, we 
quantified the number of institutions from which cancer patients were reported and 
determined whether patients seen only at one institution for their cancer differed in their 
sociodemographic and tumor characteristics from those seen at more than one institution. 
We evaluated patients newly diagnosed with any invasive cancer, with specific focus on 
those sites representing a range of care patterns (breast, prostate, lung, and pancreatic 
cancers).
2. Methods
From the Greater Bay Area Cancer Registry (GBACR), funded by the California Cancer 
Registry and the National Cancer Institute Surveillance, Epidemiology, and End Results 
(SEER) program, we obtained reports from all medical facilities for patients newly 
diagnosed with an invasive cancer during a two-year period (1/1/2010-12/31/2011) while 
resident in one of the GBACR’s nine Northern California catchment counties (Alameda, 
Contra Costa, Marin, Monterey, San Benito, San Francisco, San Mateo, Santa Clara, Santa 
Cruz). We examined all cancers combined and four site- specific cancers representing a 
spectrum of care – breast and prostate cancers have detailed clinical practice guidelines and 
generally favorable survival, while lung and pancreatic cancers are rapidly fatal and require 
more complex care. We defined these specific cancers as follows, using International 
Classification of Diseases-Oncology 3rd edition site and histology codes: breast C500–509, 
prostate C619, lung C340–349, pancreas C250–259, including all histologies except 9050–
9055, 9140, and 9590–9992.
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For analysis, we obtained patient and tumor characteristics from the GBACR (routinely 
abstracted from the medical record), including age at diagnosis, sex, race/ethnicity (non-
Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic Asian/Pacific Islander, 
hereafter referred to as white, African-American, Hispanic, and Asian/PI, and other/
unknown), AJCC stage at diagnosis, primary source of payment at the time of initial 
diagnosis or treatment (health insurance status), and a composite measure of neighborhood 
socioeconomic status (nSES) based on census block group of residence at diagnosis [8]. 
Patients were assigned an nSES quintile based on the distribution of nSES across all census 
block groups in California.
From the GBACR patient “admissions-level” database (i.e., data reflecting each institutional 
report per patient for a specific tumor rather than institutional-level data consolidated to the 
tumor level, as is reported to SEER and the CCR, and available for research), we obtained 
the names of all medical facilities (public and private hospitals; freestanding surgery, 
radiation, or pathology centers; private physician offices) reporting that they had diagnosed 
or treated a given cancer within 365 days of the first report. Over the study time period, 
59,672 invasive tumors were reported to the GBACR from 205 facilities, including at least 
85 located outside the registry’s catchment area. We grouped facilities into two types: those 
that were part of an integrated health system (IHS) (n = 35) known to share medical record 
systems and for which access is based on specific insurance coverage (i.e., Kaiser 
Permanente, Veterans Affairs systems), and those that were not (called non-IHS institutions) 
(n = 170). Private physician offices were counted as a single entity. We then grouped patients 
into four mutually exclusive categories: 1) reported from an IHS only; 2) reported from an 
IHS and at least one non-IHS institution; 3) reported from a single, non-IHS institution only; 
4) and reported from two or more non-IHS institutions. For patients with any invasive cancer 
and for those with any of the four specific cancer types described above, we calculated 
frequencies and percentages of patients in these four categories. To describe whether 
diagnostic or therapeutic care was reported by each hospital, we utilized the Commission on 
Cancer definitions of “class of case” [9]. Unfortunately, cancer registry data items do not 
distinguish whether care was inpatient or outpatient or whether it was coordinated among 
different non-IHS institutions.
2.1. Statistical analysis
To understand independent patient and tumor characteristics associated with numbers of 
institutions from which patients were reported, we used multivariable logistic regression 
analyses to calculate adjusted odds ratios (OR) and 95% confidence intervals (CI) associated 
with being reported by multiple institutions as compared to a single institution (in groups 
stratified by any report by IHS). All P values reported are two-sided, and those <0.05 are 
considered statistically significant.
3. Results
In this region, 17% of cancers newly diagnosed in the study period were reported by 
multiple institutions. Among the 33% of cancers ever reported by an IHS, 8% were 
additionally reported by an institution outside the IHS, with higher proportions among 
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patients with breast cancer (11%) than pancreatic cancer (6%) (Table 1). Among the 66% of 
patients reported only by non-IHS institutions, a much higher proportion (21%) was reported 
by multiple institutions; these proportions varied by cancer site, with higher proportions 
among patients with breast (28%) and pancreatic (27%) cancer than lung (19%) and prostate 
(18%) cancer.
Table 2 shows that, for patients reported for cancer care by multiple institutions, the most 
common pattern involved one institution reporting the diagnosis and treatment and 
additional institution(s) also reporting treatment; this situation occurred for approximately 
three-quarters of all cancer patients reported by at least one IHS, and about half of all cancer 
patients never reported by any IHS. Smaller proportions of patients were diagnosed at one 
institution and then treated at another institution(s). In general, patients reported by an IHS 
were more likely to have received some or all treatment at another institution than patients 
never reported by an IHS, who were more likely to have received diagnostic services from 
multiple institutions. Reasons for multiple institution reports varied for the specific cancer 
sites, with higher proportions of pancreatic cancer than breast cancer patients receiving 
diagnostic services from multiple institutions, irrespective of IHS report.
Table 3 shows patient and tumor characteristics of the non-IHS patients reported by multiple 
vs. single institutions. For all invasive cancers combined, the most important independent 
predictor of being reported by non-IHS multiple institutions was younger age at diagnosis; 
patients under age 65 at diagnosis were more than two times as likely, and patients under age 
44 were more than three times as likely, as those 75 years of age or older to be seen at 
multiple institutions. Patients with later stage of disease at diagnosis (stage II, III or IV) 
were more than one and one-half times as likely as patients with stage I disease to be 
reported by multiple institutions. Females were somewhat more likely than males to be seen 
at multiple institutions. Compared to white patients, Asians/PIs were more likely to be 
reported by multiple institutions. For most cancer sites, unknown status of variables (stage, 
race, health insurance) were inversely associated with being reported by multiple 
institutions, albeit based on small numbers of patients. For breast, prostate and lung cancers, 
patterns of association were generally similar to those seen for all invasive cancers, although 
associations with being reported at multiple institutions were particularly marked for 
prostate cancer patients with later AJCC stage II–IV disease (vs stage I) and for breast 
cancer patients with public insurance (vs. private/military insurance). However, for 
pancreatic cancer, patients with AJCC stage II disease at diagnosis (vs stage I) or without 
health insurance were more likely to be reported by multiple institutions, while pancreatic 
cancer patients who lived in the lowest SES neighborhoods were less likely to be reported by 
multiple institutions.
Table 4, which shows similar analyses for patients reported by at least one IHS, suggests 
generally similar associations across the cancer site categories, with younger age and later 
stage at diagnosis representing the most important and consistent indicators of being seen by 
institution(s) outside the IHS. However, for pancreatic cancer patients, none of the factors 
assessed was associated with outside facility use; and black breast cancer patients, and 
Hispanic and Asian/PI patients with any cancer, were less likely than whites to have been 
seen by outside institution(s).
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4. Discussion
Population-based data from a large urban region of California showed that nearly one 
quarter of all non-IHS patients overall, and nearly one-tenth of all IHS patients (comprising 
more than one- third of all cancer patients), received some care from at least two institutions 
within 365 days of their cancer diagnosis. Most such patients were diagnosed and received 
some treatment at one institution and additional treatment at another institution(s). Patients 
reported by multiple institutions were more likely to have been younger and have had more 
advanced stage disease at diagnosis than those seen at single institutions. However, they 
generally were not more likely to have certain kinds of insurance or to live in more affluent 
neighborhoods. Among patients with one of the four specific cancer types investigated, 
additional patient characteristics, such as having no health insurance, were associated with 
multiple institution use; this was particularly true for pancreatic cancer. Patients reported 
from an IHS also were seen at additional institutions, although, as expected, in smaller 
proportions, likely due to insurance coverage and the need to pay out-of-pocket for care 
received outside of the IHS. Despite this, however, the proportion was meaningful for breast 
and lung cancer, for which more than one in ten patients was also seen outside the IHS.
Our findings indicate that the prevalence of multiple institution use for cancer care is 
substantial at the population level, at least in this urban California region. Our data further 
show that most patients receive care from multiple institutions to obtain additional treatment 
after being diagnosed and receiving some treatment at the first institution. Lower proportions 
of patients were reported as having been diagnosed at the first institution and then treated at 
the second. While we considered cancer registry data as an important resource for estimating 
the prevalence of multi-institutional care, our cancer registry data were limited in the detail 
needed to comprehensively assess the specific kinds of services (i.e., scans, surgery, 
chemotherapy) being provided in what sequence by what institution. Patients might seek 
initial treatment or additional treatment from a second facility for many reasons, including 
referral by their first physician, out-sourcing of treatment by the patient’s primary facility, 
changes in health insurance or residence during treatment, or dissatisfaction with care or 
geographic proximity of the first institution. They might receive treatment first from 
inpatient and later from outpatient facilities. Unfortunately, other than being able to separate 
reports from IHS from non-IHS, our cancer registry resource does not collect the 
information that might enlighten these reasons further. However, in cancer registry data 
covering larger geographic areas, it would be important to carry out further assessments of 
detailed hospital characteristics (e.g. number of beds, cancer center status, volume of cancer-
specific patients, and geographic proximity to higher volume hospitals) associated with 
referral and multiple facility use.
Population-based patterns of cancer care involving multiple institutions are not well 
described in the literature. To our knowledge, only two prior studies have quantified the 
percentage of cancer patients seen at two or more institutions, and these also suggest a 
substantial prevalence of this phenomenon [10,11]. When the records of breast cancer 
patients seen at a community hospital were linked with those of a nearby academic 
institution, 16% of patients were found to have been seen at both institutions [10]. Those 
patients were significantly more likely than the patients seen at one institution to be under 
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age 40 at diagnosis, to be Asian/PI, to live in the highest SES neighborhoods, and to have 
prognostic factors (including stage, grade, subtype) that were intermediate to patients 
singularly seen at the two facilities [10]. For breast cancer patients, our population-based 
results confirm associations of multiple facility use with younger age and stage II/III, but not 
with race or neighborhood SES. Among Medicare recipients with stage III colorectal cancer, 
37% received surgery and oncology services from different hospitals [11]. Rural patients 
were more likely to be seen at multiple hospitals, and although there were no associations 
with cancer specific survival, costs were noted to be higher for patients seen at multiple 
hospitals [11]. In non-oncology settings, a study of Massachusetts patients seeking acute 
care found that 31% visited at least two hospitals over a five-year period [12] and a team 
building electronic medical record-based algorithms to identify patients with type 2 diabetes 
reported substantial data fragmentation across institutions, such that using data from two 
institutions greatly improved the predictive value of their search over using data from only 
one institution [13].
Patterns of cancer care involving multiple institutions are difficult to study, as most 
institutions do not have systematic access to records from other institutions, and multi-
institution data resources may pool together de-identified records instead of formally linking 
identified records. Central cancer registries receive reports of any first admission to a facility 
for a given cancer occurring among residents of defined geographic areas. For public health 
surveillance and research use of their data, registries consolidate this admissions information 
into a single tumor record; thus, data users do not have ready access to information 
regarding the full complement of physicians and/or institutions reporting the same patient 
for the same cancer. A strength of our approach included leveraging these detailed, 
unconsolidated registry data to provide a first assessment of the population- based 
prevalence of care from multiple institutions. Unfortunately, our data also have a number of 
limitations, most importantly not including the detailed items needed to assess the full 
spectrum of care received from specific types of institutions nor to the reasons why patients 
changed institutions. In addition, although our registry receives reports from some facilities 
outside our catchment region, our assessment may not have captured care provided by 
smaller, out-of-state hospitals without reporting relationships with the California registry. 
Thus, our estimates likely underestimate the true extent to which patients obtain care at 
multiple facilities. In addition, although we characterized patients seen at multiple facilities 
for both cancer overall and for selected site-specific cancers, we did not examine 
characteristics for all individual cancer types. Lastly, it documents multiple facility use in 
one large urban region in California, but may not be representative of other populations, 
especially those with a lower geographic concentration of hospitals.
Others have noted that data are likely to be missing from the electronic health records of 
patients who interact with multiple, nonintegrated healthcare providers [5,6]. To our 
knowledge, ours is the first study quantifying and describing basic patterns of cancer care 
involving multiple institutions at the population-level. As the prevalence of patients 
receiving care from more than one institution in this region was high, especially outside the 
IHS setting, future studies should characterize reasons for and details of care being received 
by patients across institutions to inform the types of clinical data most likely to be missing 
from a single institutional record. In particular, work should be carried out to understand the 
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implications of this missing data on quality indicators. Our findings underscore the value of 
population-based data resources, including cancer registries and linked registry- claims data 
(e.g., SEER-Medicare [14]), to broadly informative future health services studies. These 
include studies addressing comparative effectiveness, quality of care, and clinical learning 
systems, as they highlight the crucial benefit of including systematically reported 
information from all institutions involved in patient care. Researchers planning quality 
assessment or comparative effectiveness research projects based on medical records from a 
single institution or IHS should be attentive to the possibility of missing data or other bias.
Acknowledgments
Financial support
This study was supported by the Stanford Cancer Institute (to CAC) and the National Cancer Institute’s 
Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C.
Disclaimer
The collection of cancer incidence data used in this study was supported by the California Department of Public 
Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 
103885; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract 
HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C 
awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health 
Institute; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under 
agreement U58DP003862-01 awarded to the California Department of Public Health. The ideas and opinions 
expressed herein are those of the author(s) and endorsement by the State of California, Department of Public Health 
the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and 
Subcontractors is not intended nor should be inferred.
References
1. Abernethy AP, Etheredge LM, Ganz PA, et al. Rapid-learning system for cancer care. J Clin Oncol. 
2010; 28:4268–4274. [PubMed: 20585094] 
2. Friedman CP, Wong AK, Blumenthal D. Achieving a nationwide learning health system. Sci Transl 
Med. 2010; 2:57cm29.
3. Ginsburg GS, Staples J, Abernethy AP. Academic medical centers: ripe for rapid-learning 
personalized health care. Sci Transl Med. 2011; 3:101cm27.
4. Miriovsky BJ, Shulman LN, Abernethy AP. Importance of health information technology, electronic 
health records, and continuously aggregating data to comparative effectiveness research and 
learning health care. J Clin Oncol. 2012; 30:4243–4248. [PubMed: 23071233] 
5. Hersh WR, Weiner MG, Embi PJ, et al. Caveats for the use of operational electronic health record 
data in comparative effectiveness research. Med Care. 2013; 51:S30–S37. [PubMed: 23774517] 
6. Bayley KB, Belnap T, Savitz L, et al. Challenges in using electronic health record data for CER: 
experience of 4 learning organizations and solutions applied. Med Care. 2013; 51:S80–6. [PubMed: 
23774512] 
7. Wingo PA, Howe HL, Thun MJ, et al. A national framework for cancer surveillance in the United 
States. Cancer Causes Control. 2005; 16:151–170. [PubMed: 15868456] 
8. Yang, J., Schupp, C., Harrati, A., et al. Developing an area-based socioeconomic measure from 
American Community Survey data. California CPIo; Fremont, California: 2014. 
9. California Cancer Registry. California cancer reporting system standards, Volume III Class of Case 
Data Item Definition. 2010
10. Kurian AW, Mitani A, Desai M, et al. Breast cancer treatment across health care systems: linking 
electronic medical records and state registry data to enable outcomes research. Cancer. 2014; 
120:103–111. [PubMed: 24101577] 
Clarke et al. Page 7
Cancer Epidemiol. Author manuscript; available in PMC 2018 January 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
11. Hussain T, Chang HY, Veenstra CM, et al. Fragmentation in specialist care and stage III colon 
cancer. Cancer. 2015; 121:3316–3324. [PubMed: 26043368] 
12. Bourgeois FC, Olson KL, Mandl KD. Patients treated at multiple acute health care facilities: 
quantifying information fragmentation. Arch Intern Med. 2010; 170:1989–1995. [PubMed: 
21149756] 
13. Wei WQ, Leibson CL, Ransom JE, et al. Impact of data fragmentation across healthcare centers on 
the accuracy of a high-throughput clinical phenotyping algorithm for specifying subjects with type 
2 diabetes mellitus. J Am Med Inform Assoc. 2012; 19:219–224. [PubMed: 22249968] 
14. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-medicare data: content, research 
applications, and generalizability to the United States elderly population. Med Care. 2002; 
40:IV3–IV8.
Clarke et al. Page 8
Cancer Epidemiol. Author manuscript; available in PMC 2018 January 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Clarke et al. Page 9
Ta
bl
e 
1
Pa
tte
rn
s 
of
 in
sti
tu
tio
na
l r
ep
or
tin
g 
by
 ty
pe
 o
f i
nv
as
iv
e 
ca
n
ce
r,
 
G
re
at
er
 B
ay
 A
re
a 
of
 C
al
ifo
rn
ia
, 2
01
0–
11
.
C
an
ce
r s
ite
In
te
gr
at
ed
 h
ea
lth
 sy
st
em
 (I
HS
) in
sti
tu
tio
ns
n
o
n
-I
H
S 
in
st
itu
tio
ns
O
nl
y
IH
S 
pl
us
 o
th
er
(s)
Si
ng
le
M
ul
tip
le
n
%
n
%
n
%
n
%
B
re
as
t c
an
ce
r
26
51
89
.3
%
31
8
10
.7
%
46
81
72
.1
%
18
15
27
.9
%
Pr
os
ta
te
 c
an
ce
r
33
86
92
.5
%
27
5
7.
5%
45
78
82
.0
%
10
02
18
.0
%
Lu
ng
 c
an
ce
r
17
74
90
.1
%
19
5
9.
9%
33
07
80
.7
%
79
3
19
.3
%
Pa
n
cr
ea
tic
 c
an
ce
r
50
0
94
.0
%
32
6.
0%
84
5
73
.2
%
30
9
26
.8
%
A
ll 
in
v
as
iv
e 
ca
n
ce
rs
18
17
1
92
.5
%
14
81
7.
5%
31
55
4
78
.8
%
84
66
21
.2
%
Cancer Epidemiol. Author manuscript; available in PMC 2018 January 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Clarke et al. Page 10
Table 2
Factors associated with reporting of patients by multiple institutions, by cancer site, Greater Bay Area of 
California, 2010–11.
Primary invasive cancer site
Reported by integrated health 
system plus other institution(s)
Not reported by integrated health 
system but reported by two or more 
other institutions
n % N %
Breast
Diagnosed at one institution, treated at another 28 8.8 446 24.5
Diagnosed at one institution, treated there and at other(s) 277 87.1 1147 63.2
Multiple institutions reporting diagnosis and treatment 11 3.5 147 8.1
Diagnosed at multiple institutions, treated at one <5 0.6 75 1.1
Total 318 1815
Prostate
Diagnosed at one institution, treated at another 63 22.9 297 29.6
Diagnosed at one institution, treated there and at other(s) 193 70.2 427 42.6
Multiple institutions reporting diagnosis and treatment 8 2.9 132 13.2
Diagnosed at multiple institutions, treated at one 11 4.0 146 14.6
Total 275 1002
Lung
Diagnosed at one institution, treated at another 32 16.4 162 20.4
Diagnosed at one institution, treated there and at other(s) 147 75.4 420 53.0
Multiple institutions reporting diagnosis and treatment 5 2.6 107 13.5
Diagnosed at multiple institutions, treated at one 11 5.6 104 13.1
Total 195 793
Pancreas
Diagnosed at one institution, treated at another 7 21.9 81 26.2
Diagnosed at one institution, treated there and at other(s) 15 46.9 87 28.2
Multiple institutions reporting diagnosis and treatment <5 12.5 56 18.1
Diagnosed at multiple institutions, treated at one 6 18.8 85 27.5
Total 32 309
All invasive cancers
Diagnosed at one institution, treated at another 223 15.0 1857 22.9
Diagnosed at one institution, treated there and at other(s) 1121 75.7 4635 54.8
Multiple institutions reporting diagnosis and treatment 69 4.7 1005 11.9
Diagnosed at multiple institutions, treated at one 68 4.6 969 11.4
Total 1481 8466
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